Category and country
Therapeutics companies in Norway
7 therapeutics profiles in Norway. Every profile is hand-reviewed with leadership, certifications, and public sources.
Where does therapeutics cluster in Norway?
Oslo (5), Orsta (1), and Sandvika (1) Most visible profiles: AlgiPharma AS, Arctic Bioscience AS, Calluna Pharma AS, and Oncoinvent ASA.
Which standards are already visible?
GMP (2) Latest review: 24 April 2026. Review cycle: April 2026.
Full list
Therapeutics profiles in Norway
7 profiles match the active filter.
Current review cycle
AlgiPharma AS
SandvikaNorwayTherapeutics
Sandvika alginate-chemistry biotech developing OligoG CF-5/20, a low-G alginate oligomer in Phase 2b for cystic fibrosis mucus clearance and biofilm disruption, with EU Horizon 2020 and Cystic Fibrosis Foundation grant support.
- Lead
- Yngvar P. BergChief Executive Officer
- Scale
- Clinical-stage alginate oligomer development
Current review cycle
Arctic Bioscience AS
OrstaNorwayTherapeutics
Orsta-based marine-lipid pharma and nutraceutical company developing HRO350, a herring-roe-derived Phase IIb candidate for mild-to-moderate psoriasis, alongside the commercial Romega omega-3 phospholipid brand.
- Lead
- Christer L. ValderhaugChief Executive Officer
- Scale
- GMP clinical and commercial nutraceutical supply
Current review cycle
Calluna Pharma AS
OsloNorwayTherapeutics
Oslo clinical-stage antibody biotech targeting fibrosis and inflammation through the first-in-class anti-S100A4/S100A9 antibody CAL101, with Phase 1 completed in October 2024 and backing from Forbion.
- Lead
- Mark GaffneyChief Executive Officer
- Scale
- Clinical-stage antibody development
Current review cycle
Oncoinvent ASA
OsloNorwayTherapeutics
Oslo-listed clinical-stage radiopharmaceutical developer running Phase 2 trials of Radspherin, a radium-224 alpha-emitter microsphere for ovarian peritoneal metastases, following the October 2025 merger with BerGenBio.
- Lead
- Oystein SougChief Executive Officer
- Scale
- GMP clinical-trial-material production
Current review cycle
Thor Medical ASA
OsloNorwayTherapeutics
Oslo-listed radiopharmaceutical developer (formerly Nordic Nanovector) focused on alpha-emitter production (radium-224 and Pb-212) for next-generation cancer therapy, with pilot radionuclide production at Heroya.
- Lead
- Alf BjorsethChief Executive Officer
- Scale
- Pilot radiopharmaceutical production
Current review cycle
Zelluna ASA
OsloNorwayTherapeutics
Euronext Oslo-listed cell therapy company (formed February 2025 from the Ultimovacs and Zelluna Immunotherapy business combination) developing off-the-shelf TCR-NK cell therapies for solid tumors, with a lead MAGE-A4 program advancing toward IND.
- Lead
- Namir HassanChief Executive Officer
- Scale
- Clinical-stage cell therapy development
Current review cycle
Nykode Therapeutics
OsloNorwayTherapeutics
Oslo clinical-stage immunotherapy company running its DNA-based platform, oncology programs, and partner-facing operations from the Oslo Science Park headquarters.
- Lead
- Michael EngsigChief Executive Officer
- Scale
- Drug Development
Related brief
Read deeper on this category
EU Biotech Regulation 2026: What Changed and Who It Affects
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefFAQ
Frequently asked questions on this category
- What does "therapeutics company" mean?
- A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.
- Which European countries lead in therapeutics?
- Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.
- How are therapeutics companies verified in this directory?
- Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.
- Can I compare two therapeutic developers side by side?
- Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.
Next step
Compare companies or open the wider market.
Use the compare tool to view two or three companies side by side, or open the country hub for the full market view.